Loading...
Market
Imfinzi sales increase after FDA approval?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
AstraZeneca's quarterly financial reports
Story
FDA Approves Imfinzi Combo for dMMR Advanced Endometrial Cancer
Jun 17, 2024, 08:12 AM
The U.S. Food and Drug Administration (FDA) has approved the use of durvalumab in combination with carboplatin and paclitaxel, followed by single-agent durvalumab, for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). This approval, announced on June 14, is based on the Duo-E subgroup analysis. Durvalumab, marketed as IMFINZI®, is produced by AstraZeneca (AZN).
View original story
Similar markets
Less than $1 billion • 25%
$1 billion - $2 billion • 25%
$2 billion - $3 billion • 25%
More than $3 billion • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
